Press Releases

Articles & Videos

Reviva: The Potential Future Standard of Care for Schizophrenia

October 15, 2022  |  Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals

New Schizophrenia Drug Shows Promise of Greater Success with Fewer Side Effects

May 5, 2022 | RealClear Health article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals


Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

May 3, 2022  |  KOL Webinar featuring Leslie Citrome, MD (New York Medical College), Larry Ereshefsky, PharmD (Apex Innovative Sciences), and Laxminarayan Bhat, CEO (Reviva Pharmaceuticals)

Unboxing Biotech Video Series

March 9, 2022  |  Video series with Jahn Vandermosten of Zacks Research featuring Reviva CEO Laxminarayan Bhat

Engineered neuroreceptor-specificity set to deliver next-generation schizophrenia therapeutics

June 2021 | Nature Research article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals

This page contains links to other third party sites. Clicking on a third party link will cause you to leave our website. The third party sites are not controlled by Reviva and we are not responsible for the content. Please see our Privacy Policy for more information regarding third party links and sites.